New drug SPN-810 tested for kids with ADHD and severe behavior issues
NCT ID NCT00626236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested four different doses of SPN-810 (molindone) in 78 children aged 6 to 12 with ADHD and serious conduct problems. The main goal was to see if the drug is safe and tolerable. Researchers measured behavior changes using a special rating scale. The trial is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPN-810 (molindone)
What this could lead to
If successful, this could point toward a new treatment option for children with ADHD who also have severe conduct problems.
What could go wrong
This was a small, early-phase trial (phase 2) with only 78 children. It focused on safety and tolerability, not on proving the drug works. The results may not apply to all children, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance Research Group
Richmond, Virginia, 23229, United States
-
CNS Healthcare
Orlando, Florida, 32806, United States
-
Capstone Clinical Research
Libertyville, Illinois, 60048, United States
-
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
-
Florida Clinical Research Center
Bradenton, Florida, 32408, United States
-
IPS Research
Oklahoma City, Oklahoma, 73103, United States
-
Northwest Clinical Trials
Bellevue, Washington, 98004, United States
-
Sarkis Clinical Trials
Gainesville, Florida, 32607, United States
-
The Psychopharm Research Cntr - LSU Dept of Psychiatry
Shreveport, Louisiana, 71103, United States